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A Physiologically-Based Quantitative Systems 
Pharmacology Model of the Incretin Hormones  
GLP-1 and GIP and the DPP4 Inhibitor Sitagliptin
Pavel Balazki1,2,3, Stephan Schaller3, Thomas Eissing2 and Thorsten Lehr1,*
Incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) play a major role 
in regulation of postprandial glucose and the development of type 2 diabetes mellitus. The incretins are rapidly metabolized, 
primarily by the enzyme dipeptidyl-peptidase 4 (DPP4), and the neutral endopeptidase (NEP), although the exact metaboliza-
tion pathways are unknown. We developed a physiologically-based (PB) quantitative systems pharmacology model of GLP-1 
and GIP and their metabolites that describes the secretion of the incretins in response to intraduodenal glucose infusions and 
their degradation by DPP4 and NEP. The model describes the observed data and suggests that NEP significantly contributes 
to the metabolization of GLP-1, and the traditional assays for the total GLP-1 and GIP forms measure yet unknown entities 
produced by NEP. We further extended the model with a PB pharmacokinetics/pharmacodynamics model of the DPP4 inhibi-
tor sitagliptin that allows predictions of the effects of this medication class on incretin concentrations.
The incretin hormones glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP) are 
crucial for the regulation of postprandial glucose levels. 
The peptides are secreted from endocrine cells located in 
the gut mucosa as a response to meal ingestion1 and con-
tribute to controlling blood glucose levels by potentiating 
insulin secretion (GLP-1 and GIP) and decreasing the gas-
tric emptying rate (GLP-1).
Secreted GLP-1 and GIP are subject to rapid metaboliza-
tion by the enzyme dipeptidyl peptidase 4 (DPP4), which is 
expressed on the membranes of various tissues, including 
the endothelial cells2 and can be found in soluble form in 
blood plasma.3 The enzyme converts the biologically ac-
tive forms GLP-1 (7-36)amide to GLP-1 (9-36)amide and 
GIP (1-42) to GIP (3-42) (Figure 1) with estimated half-life 
values of 2 and 7  minutes, respectively.1,4 In vitro studies 
show that GLP-1 and, to a smaller extent, GIP can also be 
metabolized by the enzyme neutral endopeptidase (NEP) 
24.11.5 Although the contribution of NEP to the degradation 
of active GLP-1 in vivo has been considered negligible,4 the 
primary metabolite GLP-1 (9-36)amide is extensively elimi-
nated by NEP in pigs6 and mice.7
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Glucagon-like peptide-1 (GLP-1) and glucose-de-
pendent insulinotropic polypeptide (GIP) are rapidly me-
tabolized by dipeptidyl-peptidase 4 (DPP4), but recent 
data suggest the presence of further metabolization pro-
cesses. No mathematical models of incretins with mecha-
nistic description of the processes exist.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  Development of a mathematical model of secretion and 
metabolization of GLP-1 and GIP and a DPP4 inhibitor 
based on the current knowledge of the underlying mecha-
nisms for integration into computational diabetes platforms.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  The model allows predictions of the unknown GLP-1 
metabolite and the effect of DPP4 inhibitors based on 
their mode of action. Analysis of incretins data across 
different sources stresses the need in standardization in 
GLP-1 and GIP measurements to assess the interindivid-
ual variability.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY 
OR TRANSLATIONAL SCIENCE?
✔  The study reveals the importance of pathways other 
than DPP4-mediated degradation in metabolization of 
the incretins. New treatments targeting the new pathway 
could be developed. The mechanism-based model al-
lows in silico testing of such new therapies and predic-
tions of personalized treatment outcomes for medication 
combinations.
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Due to its importance in glucose homeostasis, the incretin 
system is a promising target for the treatment of type 2 diabe-
tes mellitus (T2DM). The common strategy is to either increase 
the concentrations of active endogenous GLP-1 by inhibition 
of DPP4,8 or to design GLP-1 analogues that are protected 
from degradation by DPP4.9 GIP was not considered a po-
tent drug target for the treatment of T2DM for a long time. 
However, the interest in GIP may increase, as recently a dual 
GLP-1 and GIP receptor agonist has demonstrated superior 
glycemic control compared with pure GLP-1 agonists.10
Concentrations of intact GLP-1 after administration of 
DPP4 inhibitors (DPP4is) increase by less than twofold.11,12 
The understanding of this relatively small effect of DPP4i de-
pends on correct assumptions regarding the mechanisms 
of incretin’s metabolization. However, the high heterogeneity 
and poor comparability of reported incretin concentration 
data does not allow to clearly define the processes involved 
in the degradation of GLP-1 and GIP. Most of the investi-
gators do not distinguish between the intact forms of the 
peptides and their primary metabolites and report “total” 
concentrations, which are assumed to be the sum of the 
active forms and the DPP4-produced metabolites. This as-
sumption is challenged by the work of Albrechtsen et al.13 
who developed an assay specific for GLP-1 (9-36)amide. 
The assay revealed that the sum of GLP-1 (7-36)amide and 
(9-36)amide concentrations is lower than the measured total 
concentration,13 suggesting the presence of an additional 
form of GLP-1 detected by the “total” assays and a possibly 
bigger role of NEP in metabolization of the incretins.
As for today, no mathematical models exist that would allow 
to quantitatively describe and predict the dynamics of the 
different forms of the incretins. In this work, we present a phys-
iologically-based (PB)14 quantitative systems pharmacology 
model of GLP-1 and GIP metabolism and secretion to (i) assess 
and investigate the sources of variability in reported incretin 
concentrations, to (ii) provide a reliable model of endogenous 
incretins for the integration in digital diabetes disease plat-
forms, and (iii) to develop and integrate a PB pharmacokinetic 
(PK) model of the DPP4i sitagliptin and its pharmacodynamic 
(PD) mechanisms to predict the effects of DPP4i therapy.
METHODS
The presented open source ordinary differential equations 
based quantitative systems pharmacology model was de-
veloped with PK-Sim and MoBi as part of the Open Systems 
Pharmacology Suite, version 8.15 Figures were created in 
R16 with the Open Systems Pharmacology Suite Toolbox 
for R (version 8).
The PBPK models were created in PK-Sim and coupled 
in MoBi. Unknown parameter values were estimated by 
fitting the model to experimental data with the parameter 
Figure 1 Physiology of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) pharmacokinetic 
as modeled. GLP-1 and GIP are produced in the L-cells and K-cells of intestinal mucosa, respectively. The uptake of glucose from 
the gut lumen by the sodium/glucose cotransporter 1 (SGLT1) transporters enhance the secretion of the incretins. After secretion 
into interstitial space, the hormones are transported through the whole body by plasma and lymph flows. GLP-1 (7-36)amide is 
metabolized by dipeptidyl-peptidase 4 (DPP4; located in plasma and endothelial membrane) to GLP-1 (9-36)amide and by neutral 
endopeptidase (NEP; located in endothelial membrane) to an unknown metabolite. GLP-1 (9-36)amide is also metabolized by NEP to 
the unknown metabolite, which is removed renally. GIP (1-42) is metabolized by DPP4 to GIP (3-42)amide. Additionally, GIP (1-42)amide 
and (3-42)amide are removed by NEP. Assays measuring total GLP-1 concentration are assumed to measure the sum of GLP-1 (7-36)
amide, GLP-1 (9-36)amide, and the unknown metabolite. Assays measuring the total GIP concentration are assumed to measure the 
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identification tool in MoBi, applying a combination of the 
Levenberg–Marquardt and Monte–Carlo algorithms.
Parameters describing metabolization of GLP-1 and GIP 
were estimated by fitting the model to one data set report-
ing the concentrations of GLP-1 (and its metabolites) and 
one data set reporting the concentrations of GIP, respec-
tively. The other data sets listed below were used for model 
qualification.
Data sets used for the definition and validation of 
GLP-1 metabolization processes are listed in Table S1 
and include concentration-time measurements during i.v. 
infusions of GLP-1 with infusion rates ranging between 0.5 
and 2 pmol/kg body weight (BW)/min. In total, 24 GLP-1 
concentration data sets were extracted. Six sources were 
excluded from the comparison as the reported dose-nor-
malized concentrations markedly differed from the values 
reported in other sources; these are marked as “outlier” in 
Table  S1.
Data sets used for the definition and validation GIP me-
tabolization processes are listed in Table S2. The seven 
data sets include concentration-time profiles of GIP during 
i.v. infusions with infusion rates ranging between 0.8 and 
16 pmol/kg BW/min.
Data sets used for the definition and validation of the 
secretion processes are listed in Table S3. The data sets 
include concentration-time profiles of GLP-1 and GIP 
during intraduodenal (i.d.) infusions of glucose at rates 
ranging from 0.71 to 4  kcal/min. The choice of i.d. infu-
sion protocols rather than oral administrations of glucose 
allows to exclude the influence of gastric emptying and to 
assess the impact of intestinal lumen exposure to glucose 
in a controlled setting.
Some sources report concentrations of GLP-1 and GIP 
sampled from dorsal hand veins by applying the “heat-
ed-hand” technique. Applying heat to the hand allows 
sampling of blood that is more similar to the arterial blood—
the so-called arterialized venous blood (AVB).17 AVB is 
modeled as a mixture of the standard peripheral venous 
blood as defined by PK-Sim, and arterial blood. Detailed 
description of the calculation of AVB concentrations is pro-
vided in Supplementary Text S1.
The PBPK model of sitagliptin was developed with data 
sets listed in Table S4. In total, three concentration-time 
profiles gathered after i.v. administration of sitagliptin (25, 
50, and 100 mg doses) and 21 profiles after oral (p.o.) ad-
ministrations (dose range 1.5–800  mg) were used. The 
parameters describing the PD effect of sitagliptin on inhibi-
tion of DPP4 were estimated with data sets describing DPP4 
activity in plasma after p.o. administration in the dose range 
between 1.5 and 200 mg.
All simulations discussed in this work can be found in the 
MoBi project file provided in the Supplementary Material, 
the results are depicted in Figures S1–S26.
RESULTS
The developed model describes the secretion of GLP-1 
(7-36)amide and GIP (1-42)amide and the metabolism of the 
secreted forms and their metabolites GLP-1 (9-36)amide, 
the unknown GLP-1 metabolite produced by NEP, and GIP 
(3-42)amide. The implemented processes are outlined in 
Figure 1.
Detailed descriptions of the GLP-1 and GIP metaboliza-
tion models are provided in Supplementary Text S3 and S4, 
the secretion processes are described in Supplementary 
Text S5. The PBPK/PD model of the DPP4i sitagliptin is 
described in Supplementary Text S6. Parameters of the 
incretin models are listed in Tables S5–S7, parameters de-
scribing the sitagliptin model are listed in Table S8.
GLP-1 PBPK model
GLP-1 (7-36)amide is secreted from the L-cells located in the 
intestinal mucosa4 and is converted to GLP-1 (9-36)amide 
by DPP4. The DPP4 is modeled in endothelial cell membrane 
and free floating in plasma. Reported values for plasma 
DPP4 concentrations vary between 23.5 and 5,690  ng/
mL,18–21 and the median value of 913 ng/mL with the molec-
ular weight of DPP4 of 175 kDa22 is used in the model.
As the data by Albrechtsen et al.13 indicates the presence 
of GLP-1 fragments other than GLP-1 (9-37)amide, deg-
radation of GLP-1 (7-36)amide and GLP-1 (9-36)amide by 
NEP to an unknown metabolite “GLP-1_NEP_Metabolite” is 
included. The total concentration of GLP-1 is defined as the 
sum of GLP-1 (7-36)amide, GLP-1 (9-36)amide, and GLP-1_
NEP_Metabolite concentrations. GLP-1_NEP_Metabolite is 
removed through a further degradation by NEP, the product 
of which is not measured by any GLP-1 assay. All forms are 
cleared by the kidneys through glomerular filtration and tu-
bular secretion.
The parameter values were estimated by fitting the model 
to concentration-time profiles reported by Albrechtsen 
et al.13 for the healthy group. The model accurately de-
scribes the concentrations of GLP-1 (7-36)amide, GLP-1 
(9-36)amide, and the total GLP-1 in arterial and renal blood 
plasma during an infusion of 1.5 pmol/kg BW/min of GLP-1 
(Figure 2a).
The predictions of active GLP-1 concentrations for 8 
data sets (see Table S1) are in good accordance with the 
observed values, with 11 of 75 compared points (15%) 
being outside of the twofold difference range (Figure 3a). 
The highest fold-differences between the observed and 
the predicted values are observed at basal concentrations 
of the hormone, with reported values ranging from < 111 to 
1523 pmol/L. The data sets that used the Millipore ELISA kit 
for determining active GLP-1 concentrations24,25 reported 
approximately three-fold to seven-fold higher concentra-
tions than those simulated by the model and are considered 
as outliers (Figures S17 and S18). The four other outlier 
data sets used the assays that were also applied in correctly 
predicted data sets, and no further assay-dependent bias 
was observed.
The predictions of total GLP-1 concentrations are 
compared with observed values in Figure 3b. Of the 242 
compared points from 19 data sets, 29 (12%) are outside 
of the twofold difference range. No systemic bias was ob-
served for any of the total GLP-1 assays.
The underpredictions or overpredictions of active and 
total GLP-1 do not correlate. A simulation of 1.2 pmol/kg 
BW/min GLP-1 infusion reported by Toft-Nielsen et al.26 
resulted in perfect prediction of the total GLP-1 levels, 
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but a 34% underprediction of the active concentrations 
(Figure S14). Simulation of 1 pmol/kg BW/min reported by 
Vilsbøll et al.27 resulted in very good prediction of active 
GLP-1, but the total concentrations were underpredicted 
by ~  30  pmol/L (25%; Figure S16). Both sources used 
the same assays for determining active and total GLP-1 
concentrations and the demographic characteristics of 
subjects in the studies were similar.
GIP PBPK model
GIP (1-42)amide is secreted by the K-cells4 and is converted 
to GIP (3-42)amide by DPP4. Both GIP (1-42)amide and (3-42)
amide are degraded by NEP. All forms are cleared by the 
kidneys through glomerular filtration. The total concentration 
of GIP is defined as the sum of GIP (1-42)amide and (3-42)
amide. Parameter values were estimated by fitting the model 
to concentration-time profiles obtained during i.v. infusions 
of 4 and 16 pmol/kg BW/min GIP reported by Vilsbøll et al.27
The comparison of fitted and observed GIP (active and 
total) concentrations is presented in Figure 2b. The predic-
tive performance was qualified by simulating reported i.v. 
infusion experiments (Table S2). The only data set that re-
ports the concentrations of active GIP during an infusion28 
that has not been used for parameters estimation is overpre-
dicted by 70% (Figure 3c and Figure S19). The predictions 
of total GIP concentrations were good for two data sets 
(Figures S20–S21),25,29 two other data sets were under-
predicted30 and overpredicted31 by approximately twofold 
(Figures S22–S23), and another data set32 was underpre-
dicted by approximately fourfold (Figure S24). Collected 
comparison of predicted vs. observed values is presented 
in Figure 3d.
Incretin secretion
The previous sections describe processes of incretin me-
tabolization based on data gathered from experiments with 
administration of exogenous GLP-1 or GIP. The following 
section focuses on endogenous production and secretion 
of the hormones.
GLP-1 and GIP are detected in human plasma in fasted 
conditions, implying a basal secretion of the hormones. 
The incretins are released into the interstitial space, with 
the secretion rate being calculated per L-cell or K-cell and 
multiplied by the number of respective cells in the mucosal 
segment. The numbers of endocrine cells per surface area 
mucosal tissue were extracted from literature,33 and the val-
ues applied in the model are listed in Table S9.
GLP-1 and GIP are stored in a reserve pool (RP) after their 
synthesis, with the consequent transfer to a ready-to-re-
lease pool (RRP) and subsequent release into the interstitial 
space.
The secretion of GLP-1 is biphasic, with the first phase 
correlating with duodenal glucose delivery rates,34 and 
the second phase depending on sodium/glucose cotrans-
porter (SGLT)1-mediated rate of glucose absorption.35 In the 
model, the rate of GLP-1 synthesis depends on the SGLT1-
mediated glucose absorption, whereas the secretion rate 
(i.e., release of GLP-1 from the RRP) is increased by duo-
denal glucose presence. The transfer of GLP-1 between RP 
and RRP is not regulated.
Figure 2 Performance of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) physiologically-
based pharmacokinetic models. Comparison of simulated (lines) and observed (symbols) concentrations of incretins. (a) GLP-1 (7-36)
amide, GLP-1 (9-36)amide, and total GLP-1 in arterial (AB) and renal blood (RB) during 180-minute infusion of 1.5 pmol/kg body weight 
(BW)/min GLP-1. Data from Albrechtsen et al.13 (b) GIP (1-42)amide and total GIP in peripheral venous blood (PVB) during 4 (minutes 
0–240) and 16 (minutes 340–580) pmol/kg BW/min GIP infusions. Data from Vilsbøll et al.27
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Secretion of GIP is also stimulated by SGLT1-dependent 
glucose uptake.35 To describe the observed data, glucose 
uptake additionally enhances GIP synthesis and the transfer 
between RP and RRP.
The model was fitted to intact GLP-1 and total GIP concen-
tration-time profiles gathered during i.d. infusions of glucose 
at 1.1 and 2.2 kcal/min rates reported by Schirra et al.34  
The comparison of the simulation results and measured data 
is presented in Figure 4. Data show a small initial increase 
in GLP-1 concentrations with consequent decrease below 
the basal levels during glucose infusion at a rate of 1.1 kcal/
min. Although the initial increase is captured by the model 
(Figure 4a), the decrease below the basal levels cannot be 
simulated with the current structure. At a glucose delivery 
rate of 2.2  kcal/min, a peak rise in GLP-1 concentrations 
is observed during the first 15 minutes, with a consequent 
Figure 3 Predictive performance of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) 
physiologically-based pharmacokinetic models. Comparison of simulated (y-axes) and observed (x-axes) concentrations of GLP-1 
(7-36)amide (a), total GLP-1 (b), GIP (1-42) (c), and total GIP (d). A total of 35 data sets (Tables S3 and 43) were compared. The identity 
line represents the perfect accordance between simulated and observed data. The dashed lines above and below the identity line 
mark the 2-fold and 0.5-fold difference ranges, respectively.
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decrease of the concentrations and their stabilization at 
~ 2.5 pmol/L. The model describes both, the initial peak and 
the observed plateau. In case of GIP (Figure 4b), the rise of 
hormone concentration is proportional to the rate of glucose 
infusion.
Reported experiments of i.d. glucose infusions (Table S3) 
were simulated to assess the predictive performance of 
the model. Although the general qualitative behavior of 
incretins secretion is well-captured, the absolute values 
differ between the simulations and reported data to var-
ious extents.
Notably, plasma concentrations of GLP-1 (Figure S25) 
declined below the basal levels at low glucose infusion 
rates.36–38 Whereas the 2.2 kcal/min glucose infusion triggers 
a distinct GLP-1 response in the data set used for model de-
velopment,34 the 2 kcal/min infusion in the data set reported 
by Ma et al.37 does not induce any steady-state increase in 
GLP-1 concentrations, and the values are below those of 
saline infusion. The model simulates a distinct response in 
the first 20 minutes, in accordance with the observations of 
Schirra et al.34
Predictions of GIP response to i.d. glucose (Figure S26) 
are quantitively less reliable than the predictions of 
GLP-1 concentrations. Although the infusions reported by 
O’Donovan et al.38 are predicted within a twofold differ-
ence, the data by Schirra et al.36 and Ma et al.37 are strongly 
overpredicted. However, Schirra et al.36 do not clearly 
state whether the GIP assay measured the total or the 
active concentrations, and the simulated active concen-
trations are in accordance with the reported data, whereas 
the total concentrations were overpredicted by almost 
threefold (170 vs. 64 pmol/L). Ma et al.37 reports unusually 
low total GIP concentrations (8 pmol/L), and the basal sim-
ulated values are several-fold higher (22.8 pmol/L).
Model of sitagliptin PKs/PDs
The PBPK model of sitagliptin as a representative com-
pound for the class of DPP4i was developed using 
information reported in literature and in the DrugBank33 da-
tabase (accession number DB01261). The model includes 
active transport of sitagliptin by the transporters P-gp and 
human organic cation transporter 3,39 glomerular filtra-
tion, reversible binding to DPP4, as well as metabolization 
through cytochrome P450 3A4 (CYP3A4).
Although sitagliptin is reported to be highly soluble across 
the physiological pH range and the tablet formulation used in 
the final product is rapidly dissolving,40 the reported concen-
tration-time profiles show delayed absorption with plasma 
concentrations plateauing between 2 and 4 hours postdose 
at doses up to 200 mg.41 Furthermore, ~ 11% of an 83 mg 
oral dose were excreted via feces.42 A model with limited 
intestinal permeability in combination with P-gp-mediated 
efflux could not describe these observations.
We hypothesize that sitagliptin is reversibly bound to 
DPP4-like proteins in gut microbiota43 prior to absorption, and 
traverses the lumen together with the microbiome. The model 
includes synthesis of DPP4-like proteins in lumen segments, 
reversible binding of sitagliptin, and transfer along the lumen.
Parameter values were identified by fitting the model 
to concentration-time profiles after i.v. and p.o. adminis-
trations of sitagliptin, the data sets are listed in Table S4. 
The model allows adequate description of sitagliptin PK 
(Figure 5a,b) with simulated 11% of 83 mg oral dose ex-
creted to feces (observed 11%42) and 16% metabolized by 
Figure 4 Secretion of the incretin hormones during intraduodenal glucose infusion. Comparison of simulated (lines) and observed 
(symbols) concentrations of incretins during 1.1 and 2.2 kcal/min intraduodenal infusions of glucose.33 (a) Glucagon-like peptide-1 
(GLP-1) (7-36)amide. (b) Total glucose-dependent insulinotropic polypeptide (GIP).
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CYP3A4 (reported total oxidative metabolization 16%42). 
The total comparison of 256 data points from 23 data sets is 
presented in Figure 5c, with 11 points (4%) being outside of 
the twofold difference range.
Inhibition of DPP4 by sitagliptin is modeled as reversible 
binding of the drug to the enzyme. The percentage inhibition 
of plasma DPP4 is modeled as the percentage of plasma 
DPP4 bound to sitagliptin and is described well in dose-de-
pendent manner (Figure 5d).
To assess the predictive performance of the pharmaco-
logical effect of sitagliptin, we simulated the study reported 
by Andersen et al.12 Eight patients with T2DM received a 
continuous i.v. infusion of 1  pmol/kg BW/min GLP-1 fol-
lowed by oral administration of 0 (placebo), 25, 100, or 
Figure 5 Performance of the sitagliptin physiologically-based pharmacokinetic/pharmacodynamic model. (a) Comparison of simulated 
(lines) and observed (symbols) concentrations of sitagliptin after iv administration. Data from Bergman et al.49 (b) Oral administration 
of sitagliptin. Data from Herman et al.41 (c) Comparison of simulated (x-axis) and observed (y-axis) concentrations of sitagliptin. A total 
of 256 points from 23 data sets were compared. The identity line represents the perfect accordance between simulated and observed 
data. The dashed lines above and below the identity line mark the 2-fold and 0.5-fold difference ranges, respectively. (d) Comparison 
of observed and simulated inhibition (in % of basal activity) of plasma dipeptidyl-peptidase 4 (DPP4) after oral administration of 
sitagliptin.
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200  mg sitagliptin. Arterialized venous plasma concentra-
tions of active GLP-1 were measured.
The reported basal value of about 18 pmol/L active GLP-1 
is unusually high, being a clear outlier compared with basal 
values reported in other sources (mean value of 3.9 pmol/L). 
The basal value simulated by the model is 1.8 pmol/L, and the 
reported value can only be simulated by disabling both the 
DPP4-mediated and NEP-mediated metabolization processes 
or increasing the basal secretion rate by more than 10-fold. 
We, therefore, decided to compare percentage increase in 
GLP-1 concentrations after administration of sitagliptin rather 
than the absolute values.
Administration of 25  mg sitagliptin increases the con-
centrations of GLP-1 by up to 51% (62 vs. 41  pmol/l) in 
the observed data, and by 63% in the simulations (36 vs. 
22 pmol/l). The increase of the sitagliptin dose to 200 mg 
leads to only a minor further increase in peak GLP-1 concen-
trations (to 65 pmol/L). Consistent with these observations, 
the model predicts 4  pmol/l higher GLP-1 concentrations 
with administration of 200 mg compared with the adminis-
tration of 25 mg sitagliptin, as shown in Figure 6a. Figure 6b 
presents the simulated effect of sitagliptin administration 
on the concentrations of active GIP during the infusions of 
4 pmol/kg BW/min GIP. The increase of intact GIP concen-
trations during hormone infusion amounts to 54% and is 
comparable to that seen for GLP-1.
DISCUSSION
Until recently, only the total or the active forms of GLP-1 
could be measured, and it has been assumed that the total 
form consists of GLP-1 (7-36)amide and the metabolite 
formed by DPP4. A recent advance in developing a GLP-1 
(9-36)amide assay by Albrechtsen et al.13 reveals the pres-
ence of a yet uncharacterized form. This discovery paves 
the way for better understanding of GLP-1 metabolism and 
development of more precise models. The observed con-
centrations of all three measured forms (GLP-1 (7-36)amide, 
GLP-1 (9-36)amide, and total GLP-1) can be described by a 
model incorporating the degradation of GLP-1 (7-36)amide 
and (9-36)amide by NEP, pointing to the potential impor-
tance of the enzyme.
During model development we were confronted with high 
heterogeneity of reported GLP-1 concentrations, (basal values 
between < 134 and 2012 pmol/L). This variability can be partly 
attested to the differences in the specificity and sensitivity of 
available assays,44 whereas no biological factors could be 
identified. Because the modeled elimination processes scale 
linearly in the physiological concentration range, an underpre-
diction or overprediction of an i.v.-infusion experiment reflects 
the differences between the data sets after dose normaliza-
tion. Based on this assumption, we excluded the six data sets 
that reported steady-state concentrations that are >  100% 
higher than dose-normalized (and thus predicted) from the 
analysis as “outliers.” As the mean demographic character-
istics between the groups did not markedly differ, reliable 
conclusions about the sources of the observed differences 
cannot be made and incorporated in the model.
Neither the cross-compatibility of the results nor the 
choice of a certain assay are discussed within the studies, 
and direct comparison of the observed results seems diffi-
cult. To assess the interindividual variability in GLP-1 levels 
Figure 6 Simulation of sitagliptin effect on incretin concentrations. Administration of 200 mg sitagliptin was simulated at time 0. At 
time 20 minutes, an infusion of 1 pmol/kg body weight (BW)/min glucagon-like peptide-1 (GLP-1 (a) or 4 pmol/kg BW/min glucose-
dependent insulinotropic polypeptide (GIP) (b) was initiated and lasted for 360 minutes. Shown is the simulated concentration in 
arterialized venous blood.
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and to identify the causes, a consistent data set produced 
under similar conditions, including measurements of at 
least the active and the total forms, is required. We further 
conclude that studies assessing the metabolic state of an 
individual (e.g., an oral glucose tolerance test) should re-
port both, the total and the intact concentrations of GLP-1. 
Because total GLP-1 concentrations are not affected by the 
activity of DPP4 (and, potentially, NEP), they can be used to 
derive the secretory capacity of an individual, whereas intact 
GLP-1 concentrations reflect the biologically active moiety. 
Only measuring the total GLP-1 concentrations, as it has 
been proposed,44 would not reflect the variability observed 
in DPP4 activity.45
The challenges of model validation and variability assess-
ment are especially true for the GIP PK model. Available 
data on GIP secretion is highly inconsistent.46 With the 
limited data available, an accurate characterization of GIP 
metabolism is not possible. Only one data set27 reports the 
concentrations of both, the active and total forms of GIP, but 
the metabolite has not been directly measured so far.
The presented model describes incretin responses to in-
gested glucose as the most prominent secretagogue. The 
responses to i.d. infusions of glucose reported by Schirra 
et al.34 are accurately reproduced. This peak originates from 
the initially enhanced release of GLP-1 molecules from RRP 
vesicles, and the intensity of the peak is primarily deter-
mined by the size of the RRP. After the RRP is depleted, 
concentrations of GLP-1 slightly decrease, followed by a 
steady increase due to an increased synthesis rate. The se-
cretion of GIP is proportional to the rate of glucose delivery 
and does not show a biphasic pattern.
The predictions of GLP-1 and GIP responses are in 
acceptable quantitative and qualitative agreement with 
data,36,38 except for the several-fold overprediction of the 
GIP concentrations reported by Ma et al.37 Although the 
cause of this overprediction cannot be identified, it can be 
described by varying the K-cell and L-cell density in the 
intestinal mucosa or the basal secretion rates. No study, 
however, reports the concentrations of both, the active and 
the total, forms of the incretins during i.d. glucose infusion, 
making it impossible to differentiate between the variability 
in incretin secretion and metabolization. Furthermore, vari-
ability in the positioning of the catheter for glucose infusion 
in the duodenum could introduce significant variability in the 
observations.
The mechanistic description of the degradation of in-
cretins enables predictions of the effects of specific DPP4 
inhibitors. We have modeled the PK of sitagliptin and in-
corporated its inhibitory effects on the plasma soluble and 
membrane bound DPP4. The model captures the dose-de-
pendency of plasma DPP4 inhibition well, with 100 mg once 
daily being sufficient for a constant > 80% inhibition. The 
direct comparison of the predicted and observed pharma-
cological effect is not trivial as the only data set assessing 
the effect of sitagliptin on GLP-1 levels during GLP-1 infu-
sion12 reports unusually high basal and steady-state GLP-1 
concentrations. The reasons for such high deviation from 
other reported concentrations is not clear, and the com-
parison of absolute values with simulations seems not to 
be reasonable. Nevertheless, the simulated percentage 
increase in GLP-1 concentrations during i.v. infusion with 
sitagliptin administration at different doses is very close to 
the observed increase, which allows us to conclude that the 
model provides a suitable platform for predictions of DPP4i 
effects considering the high observed variability between 
the studies.
In summary, we present a model of incretin dynamics 
that incorporates the current knowledge of the underlying 
processes. The model offers a plausible and consistent de-
scription of incretin metabolism and secretion, and is the 
first of its kind that predicts concentrations of the various 
forms of incretins, including the undiscovered metabolite(s). 
We were not able to find any plausible physiological expla-
nation for the variability in reported concentrations between 
studies and conclude that the major determinants are the 
choice of the assay and the uncertainties of the experimen-
tal procedures. Given a consistent (i.e., produced under 
similar conditions) set of data on patient level, including pa-
tient characteristic to inform the physiology, the model could 
be further extended to better leverage the PBPK framework 
and identify the interindividual variability of the modeled pro-
cesses, offering a tool for population simulations. Inclusion 
of the metabolites in the model allows the distinction be-
tween the interindividual variability in incretin secretion and 
degradation and the relative contribution of the different 
metabolization pathways providing an explanation for the 
limited maximal effect of DPP4i. Furthermore, the metab-
olites allow to compare concentration data from different 
sources that only report either the active or the total form.
As the majority of data gathered in i.v. infusion experi-
ments are predicted within the twofold range, we conclude 
that the model adequately represents the mean popula-
tion. Despite the large quantitative uncertainty observed in 
i.d. glucose infusion experiments, the qualitative behavior 
of GLP-1 and GIP secretion and the effects of DPP4i are 
captured well, and the model can be considered reliable for 
predicting PD effects of the incretins and DPP4i. The model 
is freely available at http://www.open-syste ms-pharm acolo 
gy.org and, in combination with the PBPK/PD model of 
the DPP4i sitagliptin and the previously developed model 
of SGLT2 inhibitors,47 is well-suited for the integration into 
large scale diabetes models,47,48 such as to allow more de-
tailed simulations of glucose homeostasis and predictions of 
efficacy of treatment combinations in the context of transla-
tional and personalized medicine.
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